Sinco Pharmaceuticals Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Sinco Pharmaceuticals Holdings CEO'su Min Jin, Mar2023 tarihinde atandı, in görev süresi 1.67 yıldır. in toplam yıllık tazminatı CN¥ 1.96M olup, şirket hissesi ve opsiyonları dahil olmak üzere 94.6% maaş ve 5.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.67% ine doğrudan sahiptir ve bu hisseler HK$ 2.57M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 6 yıldır.

Anahtar bilgiler

Min Jin

İcra Kurulu Başkanı

CN¥2.0m

Toplam tazminat

CEO maaş yüzdesi	94.6%
CEO görev süresi	1.7yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	6yrs

Son yönetim güncellemeleri

Recent updates

What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You

Oct 04

Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Aug 16

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Apr 02

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Mar 08

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Nov 07

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Jun 26

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

May 30

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Oct 26

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Feb 04

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Oct 25

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Jun 10

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

May 24

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Apr 20

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Feb 16

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 11

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Dec 07

CEO Tazminat Analizi

Min Jin'un ücretlendirmesi Sinco Pharmaceuticals Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	CN¥47m
Mar 31 2024	n/a	n/a	CN¥44m
Dec 31 2023	CN¥2m	CN¥2m	CN¥42m
Sep 30 2023	n/a	n/a	CN¥35m
Jun 30 2023	n/a	n/a	CN¥27m
Mar 31 2023	n/a	n/a	CN¥48m
Dec 31 2022	CN¥2m	CN¥2m	CN¥69m

Tazminat ve Piyasa: Min 'ın toplam tazminatı ($USD 272.91K ) Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 236.00K ).

Tazminat ve Kazançlar: Min 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Min Jin (46 yo)

1.7yrs

Görev süresi

CN¥1,959,000

Tazminat

Mr. Min Jin is Chief Accountant since August 17, 2023 and Secretary since December 21, 2023 at Nanjing Tanker Corporation. He was Co-Chief Executive Officer at Sinco Pharmaceuticals Holdings Limited since...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xiangbin Huang	Executive Chairman	13.6yrs	CN¥7.10m	51.65% HK$ 197.4m
Min Jin	Chief Executive Officer	1.7yrs	CN¥1.96m	0.67% HK$ 2.6m
Shifeng Lei	Executive Director	no data	CN¥1.09m	Veri yok
Yifan Li	Chief Financial Officer	9.4yrs	Veri yok	Veri yok
Zhijian Huang	Executive Director	less than a year	Veri yok	Veri yok
Yunlu Peng	Company Secretary	5.1yrs	Veri yok	Veri yok
Tao Zhang	President of Sichuan Sinco Pharmaceuticals Co. Ltd.	2yrs	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

44yo

Ortalama Yaş

Deneyimli Yönetim: 6833 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xiangbin Huang	Executive Chairman	13.6yrs	CN¥7.10m	51.65% HK$ 197.4m
Shifeng Lei	Executive Director	1.7yrs	CN¥1.09m	Veri yok
Zhijian Huang	Executive Director	less than a year	Veri yok	Veri yok
Ying Kit Lau	Independent Non-Executive Director	6yrs	CN¥300.00k	Veri yok
Wenfang Liu	Independent Non-Executive Director	8.8yrs	CN¥300.00k	Veri yok
Qing Wang	Independent Non-Executive Director	8.8yrs	CN¥300.00k	Veri yok
Zhizhong Bai	Independent Non-Executive Director	4.2yrs	CN¥300.00k	Veri yok

6.0yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6833 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6 yıldır).

Sinco Pharmaceuticals Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sinco Pharmaceuticals Holdings Limited, Annual General Meeting, May 16, 2024

Sinco Pharmaceuticals Holdings Limited Resignation of Li Kin Wai as Joint Company Secretary and Appointment of Peng Yunlu as Executive Director

Sinco Pharmaceuticals Holdings Limited, Annual General Meeting, May 13, 2022

Sinco Pharmaceuticals Holdings Limited Announces Management Changes

Sinco Pharmaceuticals Holdings Limited Announces Board Changes

Sinco Pharmaceuticals Holdings Limited Appoints Jin Min as Co-Chief Executive Officer

Recent updates

What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You

First half 2024 earnings released: EPS: CN¥0.012 (vs CN¥0.01 in 1H 2023)

Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Sinco Pharmaceuticals Holdings Limited to Report Q2, 2024 Results on Aug 28, 2024

Sinco Pharmaceuticals Holdings Limited, Annual General Meeting, May 16, 2024

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Dividend reduced to HK$0.0039

Sinco Pharmaceuticals Holdings Limited Proposes Final Cash Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

Sinco Pharmaceuticals Holdings Limited Resignation of Li Kin Wai as Joint Company Secretary and Appointment of Peng Yunlu as Executive Director

Sinco Pharmaceuticals Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 20% overvalued

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Now 20% overvalued

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

New minor risk - Share price stability

First half 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.03 in 1H 2022)

Now 20% undervalued after recent price drop

Sinco Pharmaceuticals Holdings Limited to Report Q2, 2023 Results on Aug 30, 2023

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Full year 2022 earnings released: EPS: CN¥0.034 (vs CN¥0.078 in FY 2021)

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

First half 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.044 in 1H 2021)

Sinco Pharmaceuticals Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.078 (vs CN¥0.07 in FY 2020)

Sinco Pharmaceuticals Holdings Limited, Annual General Meeting, May 13, 2022

Investor sentiment improved over the past week

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Sinco Pharmaceuticals Holdings Limited (SEHK:6833) entered into a letter of interest to acquire Deyang Demei Medical Aesthetic Clinic from Jiang Biao, Jiang Min and Jiang Jun.

Investor sentiment deteriorated over the past week

Sinco Pharmaceuticals Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 206.4 million.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

First half 2021 earnings released: EPS CN¥0.044 (vs CN¥0.019 in 1H 2020)

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

Full year 2020 earnings released: EPS CN¥0.07 (vs CN¥0.014 in FY 2019)

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Joint Company Secretary has left the company

Full year 2020 earnings released: EPS CN¥0.07 (vs CN¥0.014 in FY 2019)

Sinco Pharmaceuticals Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$0.32

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Sinco Pharmaceuticals Holdings Limited Announces Management Changes

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Sinco Pharmaceuticals Holdings Limited Announces Board Changes

New 90-day low: HK$0.26

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Sinco Pharmaceuticals Holdings Limited Appoints Jin Min as Co-Chief Executive Officer

New 90-day high - HK$0.30

Sinco Pharmaceuticals Holdings Limited to Report Q2, 2020 Results on Aug 28, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş